Claims for Patent: 7,268,153

Summary for Patent: 7,268,153

Title:	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
Abstract:	Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer\'s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Inventor(s):	Hanney; Barbara (Pennsburg, PA), Kim; Yuntae (Harleysville, PA), Krout; Michael R. (Pasedena, CA), Meissner; Robert S. (Schwenksville, PA), Mitchell; Helen J. (Richboro, PA), Musselman; Jeffrey (Harleysville, PA), Perkins; James J. (Churchsville, PA), Wang; Jiabing (Chalfont, PA)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	11/145,490
Patent Claims:	1. A compound chosen from: N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-phenylbutanamide; (S)--N-(3-fluoro-5-(trifluoromethyl)benzyl)-2-phenylbutanamide; (S)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-phenylbutanamide; N-(5-bromo-2-fluorobenzyl)-2-phenylbutanamide; (S)--N-(5-bromo-2-fluorobenzyl)-2-phenylbutanamide; N-(3-fluoro-5-(trifluoromethyl)benzyl)-2-phenylbutanamide; N-(2-fluoro-5-methylbenzyl)-2-phenylbutanamide; N-(5-ethyl-2-fluorobenzyl)-2-phenylbutanamide; (S)--N-(5-ethyl-2-fluorobenzyl)-2-phenylbutanamide; N-(5-cyclopropyl-2-fluorobenzyl)-2-phenylbutanamide; N-(2-fluoro-5-vinylbenzyl)-2-phenylbutanamide; N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-fluorophenyl)butanamide; N-(5-ethyl-2-fluorobenzyl)-2-(4-chlorophenyl)butanamide; N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-phenylbutanamide; (S)--N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-phenylbutanamide; (S)--N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-phenylbutanamide; (S)--N-((2-fluoro-5-(trifluoromethyl)pyridin-3-yl)methyl)-2-phenylbutanam- ide; N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamide; (R)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamide; (S)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamide; N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-hydroxybutana- mide; (R)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-hyd- roxybutanamide; (S)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-hydroxyb- utanamide; N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenylbut- anamide; (R)--N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenyl- butanamide; (S)--N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanami- de; 2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-ph- enylacetamide; (R)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-p- henylacetamide; (S)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-p- henylacetamide; N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanamide; (R)--N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanamid- e; (S)--N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanam- ide; N-(5-ethyl-2-fluorobenzyl)-2-(3-chlorophenyl)butanamide; N-(5-ethyl-2-fluorobenzyl)-2-(3,4-dichlorophenyl)butanamide; and pharmaceutically acceptable salts and stereoisomers thereof. 2. A compound chosen from: N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamide; (2R)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamide- ; (2S)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylbutanamid- e; N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-hydroxybuta- namide; (2R)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-- hydroxybutanamide; (2S)--N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-(3-chlorophenyl)-2-hydroxy- butanamide; N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanamide; (2R)--N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanam- ide; (2S)--N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-phenylbut- anamide; 2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy- -2-phenylacetamide; (2R)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-- phenylacetamide; (2S)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-- phenylacetamide; N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanamide; (2R)--N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutanami- de; (2S)--N-((5-ethyl-2-fluoropyridin-3-yl)methyl)-2-hydroxy-2-phenylbutan- amide; 3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy- -2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; 3,3,4,4,4-pentafluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy- -2-phenylbutanamide; (2R)-3,3,4,4,4-pentafluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hy- droxy-2-phenylbutanamide; (2S)-3,3,4,4,4-pentafluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hy- droxy-2-phenylbutanamide; 3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phenylpr- opanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hyd- roxy-2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phe- nylpropanamide; 3,3,3-trifluoro-N-(2-fluoro-5-ethylbenzyl)-2-hydroxy-2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-5-ethylbenzyl)-2-hydroxy-2-phenylpropana- mide; (2S)-3,3,3-trifluoro-N-(2-fluoro-5-ethylbenzyl)-2-hydroxy-2-phenylpr- opanamide; 3,3,3-trifluoro-N-(2-fluoro-5-bromobenzyl)-2-hydroxy-2-phenylpr- opanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-5-bromobenzyl)-2-hydroxy-2-phe- nylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-5-bromobenzyl)-2-hydroxy-2-phenylpropana- mide; 3,3,3-trifluoro-N-(2-fluoro-5-chlorobenzyl)-2-hydroxy-2-phenylpropan- amide; (2R)-3,3,3-trifluoro-N-(2-fluoro-5-chlorobenzyl)-2-hydroxy-2-phenyl- propanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-5-chlorobenzyl)-2-hydroxy-2-phenylpropan- amide; 3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-ph- enylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phe- nylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phe- nylpropanamide; 3,3,4,4,4-pentafluoro-N-(2-fluoro-5-cyclopropylbenzyl)-2-hydroxy-2-phenyl- butanamide; (2R)-3,3,4,4,4-pentafluoro-N-(2-fluoro-5-cyclopropylbenzyl)-2-hydroxy-2-p- henylbutanamide; (2S)-3,3,4,4,4-pentafluoro-N-(2-fluoro-5-cyclopropylbenzyl)-2-hydroxy-2-p- henylbutanamide; 3,3,4,4,4-pentafluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-ph- enylbutanamide; (2R)-3,3,4,4,4-pentafluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy- -2-phenylbutanamide; (2S)-3,3,4,4,4-pentafluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy- -2-phenylbutanamide; 3,3,3-trifluoro-N-(2,3,5-trifluorobenzyl)-2-hydroxy-2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2,3,5-trifluorobenzyl)-2-hydroxy-2-phenylpropanam- ide; (2S)-3,3,3-trifluoro-N-(2,3,5-trifluorobenzyl)-2-hydroxy-2-phenylprop- anamide; 2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(cyclopropyl)benzy- l]-2-hydroxypropanamide; (2R)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(cyclopropyl)benzyl]-- 2-hydroxypropanamide; (2S)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(cyclopropyl)benzyl]-- 2-hydroxypropanamide; 2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-hydro- xypropanamide; (2R)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; (2S)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; 2-(4-chloro-3-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(trifluoromethyl)- benzyl]-2-hydroxypropanamide; (2R)-2-(4-chloro-3-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(trifluorome- thyl)benzyl]-2-hydroxypropanamide; (2S)-2-(4-chloro-3-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-(trifluorome- thyl)benzyl]-2-hydroxypropanamide; 3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydroxy-2-- phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; 3,3,3-trifluoro-N-(2-fluoro-3-cyano-5-trifluoromethylbenzyl)-2-hydroxy-2-- phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-3-cyano-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-3-cyano-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; 3,3,3-trifluoro-N-(2-fluoro-4-cyano-5-ethylbenzyl)-2-hydroxy-2-phenylprop- anamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-4-cyano-5-ethylbenzyl)-2-hydroxy- -2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-4-cyano-5-ethylbenzyl)-2-hydroxy-2-pheny- lpropanamide; and pharmaceutically acceptable salts thereof. 3. A compound of claim 2, chosen from: 3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phe- nylpropanamide; (2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; 3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydroxy-2-- phenylpropanamide (2R)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; (2S)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; 2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-hydro- xypropanamide; (2R)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; (2S)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; and pharmaceutically acceptable salts thereof. 4. A compound of claim 3, chosen from: (2R)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-- phenylacetamide; (2S)-2-cyclopropyl-N-((2-fluoro-5-methylpyridin-3-yl)methyl)-2-hydroxy-2-- phenylacetamide; (2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; (2R)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; (2S)-2-(4-fluorophenyl)-3,3,3-trifluoro-[2-fluoro-5-cyclopropylbenzyl]-2-- hydroxypropanamide; and pharmaceutically acceptable salts thereof. 5. A compound of claim 4, chosen from: (2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide; (2R)-3,3,3-trifluoro-N-(2-fluoro-3-bromo-5-trifluoromethylbenzyl)-2-hydro- xy-2-phenylpropanamide; and pharmaceutically acceptable salts thereof. 6. A compound of claim 5, chosen from: (2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-- 2-phenylpropanamide and pharmaceutically acceptable salts thereof. 7. A compound of(2R)-3,3,3-trifluoro-N-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydrox- y-2-phenylpropanamide. 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier. 9. A composition of claim 8, further comprising an active ingredient selected from: an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative, a bisphosphonate, an antiestrogen or a selective estrogen receptor modulator, an .alpha.v.beta.3 integrin receptor antagonist, a cathepsin K inhibitor, an HMG-CoA reductase inhibitor, an osteoclast vacuolar ATPase inhibitor, an antagonist of VEGF binding to osteoclast receptors, an activator of peroxisome proliferator-activated receptor .gamma., calcitonin, a calcium receptor antagonist, parathyroid hormone or analog thereof, a growth hormone secretagogue, human growth hormone, insulin-like growth factor, a p38 protein kinase inhibitor, bone morphogenetic protein, an inhibitor of BMP antagonism, a prostaglandin derivative, vitamin D or vitamin D derivative, vitamin K or vitamin K derivative, ipriflavone, fluoride salts, dietary calcium supplements, and osteoprotegerin. 10. A composition of claim 9, wherein said bisphosphonate is alendronate. 11. A pharmaceutical composition made by combining a compound according to claim 2 and a pharmaceutically acceptable carrier. 12. A compound chosen from: (2R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2- phenylpropanamide and pharmaceutically acceptable salts thereof. 13. A compound of ##STR00090## (2R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2- phenylpropanamide.

Details for Patent 7,268,153

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2024-06-07